Some of Wednesday's midday movers:» Read More
Check out which companies are making headlines after the bell Thursday:
San Diego is at ease with sandy beaches, and biotechnology.
TheStreet.com reports its investor predictions for FDA drug approvals in 2013: Bad news for Arena Pharmaceuticals, Delcath Systems and Aveo Pharmaceuticals, but Sarepta Therapeutics and Ziopharm are among the winners.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
TheStreet.com offers up 13 biotech predictions for 2013.
As Christmas overeating gives way to under-fulfilled new year diets, the pharmaceutical industry's appetite has been whetted for a fresh surge in business.
Here's how to profit from the coming Alexza FDA run down.
Are you ready skeedaddy??! It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
TheStreet.com details the 10 best-performing biopharmaceutical stocks of 2012 and their outlook for 2013.
Credit Suisse Securities LLC, BofA Merrill Lynch and Leerink Swann LLC will act as joint managers. The company hopes to file in late 2013, triggering a 10- month review process by the FDA. The FDA refused to approve the drug in February 2011.
Shares of Vivus Inc. tumbled Thursday after an analyst said Wall Street may be over-estimating gains from initial sales of the drug developer's obesity treatment Qsymia. THE BIG PICTURE: Qsymia, Vivus' only approved drug, launched in the U.S. in September.
CNBC's Seema Mody anticipates which pharma stocks could raise their dividends in the months ahead.
Check out which companies are making headlines after the bell Wednesday.
Large regional banks continue to outperform the money center banks, despite the compelling stock price multiples for the largest bank holding companies.
Stocks finished higher for a second session Wednesday, led by techs, after Bernanke reiterated that the central bank stands ready to inject more stimulus and despite the Fed's latest lackluster "Beige Book" report.
U.S. stock index futures held their losses Wednesday ahead of a second day of Congressional testimony from Federal Reserve chairman Ben Bernanke.
Short selling is never going to be a wildly popular investing practice, but it is perfectly legal and essential for the proper function of the capital markets. I asked a biotech short seller for his thoughts on why long investors seem so hostile to short sellers and whether this animosity will compel short sellers to be even more reluctant to voice their opinions publicly.
Jim Cramer’s researcher, Nicole Urken, reiterates the importance of assessing risk when speculating.
Investors need to see this as a speculative stock and take some profits as they come in, he said.
Find out which second-quarter top performer got the most votes.